Sino Biological, Inc. announced today that it has launched a panel of research reagents for the newly identified Omicron variant (B.1.1.529) of the SARS-CoV-2 virus, which quickly raised concerns around the world because of the high number of mutations it carries, especially the 30-plus mutations on the Spike protein.
Vifor Pharma Ltd to be acquired for CHF10.9bn
Latest NewsBiologicals and vaccine specialist CSL Ltd is set to acquire Swiss Vifor Pharma Ltd for CHF10.9bn.
Fapon Biotech Races to Introduce Omicron Neutralizing Antibodies Titer Testing Solution
ProductsGiven Omicron Varinat’s potential higher rate of transmissibility, Fapon Biotech has successfully introduced SARS-CoV-2 Omicron Variant Neutralizing Antibody Titer Testing Solution (ELISA) to effectively evaluate the immune evasiveness and vaccine effectiveness on Omicron varian.
Successor wanted
AppointmentsGabriella Björknert Caracciolo will leave Bactiguard AB, where she currently works as CFO and deputy CEO.
Apogenix gets €25.8m cash injection for asunercept
Latest NewsGerman Apogenix AG has received a €26m in funding for a pivotal Phase III study of its CD95 ligand blocker asunercept for the treatment of COVID-19 patients.
British Adendra Therapeutics closes $53m financing
Latest NewsThe 2021 spin out of London-based Francis Crick Institute is the very first UK company formation deal of life sciences investor ATP (Apple Tree Partners).
Back as CEO
AppointmentsSwedish Oncopeptides has had a new CEO since mid-November. Jakob Lindberg has taken over the position from Marty J. Duvall again. He has left the company.
Accelerating biologics development
Sponsored PublicationsAbstract: This report provides a roadmap for assessing and selecting the right partner to get promising biological therapies to patients quickly. Criteria includes:
Accelerating biologics development
Sponsored PublicationsAbstract: This report provides a roadmap for assessing and selecting the right partner to get promising biological therapies to patients quickly. Criteria includes:
Sino Biological Newly Launched A Panel of Research Reagents for SARS-CoV-2 Omicron Variant (B.1.1.529)
Sponsored PublicationsSino Biological, Inc. announced today that it has launched a panel of research reagents for the newly identified Omicron variant (B.1.1.529) of the SARS-CoV-2 virus, which quickly raised concerns around the world because of the high number of mutations it carries, especially the 30-plus mutations on the Spike protein.
Recordati bags EUSA to strengthen rare disease franchise
Latest NewsItalian pharma company Recordati is putting €750m on the table to acquire UK-based specialty pharmaceutical company EUSA Pharma.